PCN95 Pharmacoeconomic Analysis of Direct Medical Costs Associated With the Treatment of Advanced Esophago-Gastric Cancer Therapy With Xeloda or 5-Fluorouracil (5-FU) Regimens- Implications for Health Care Utilisation in Australia
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.2135
https://www.valueinhealthjournal.com/article/S1098-3015(12)03849-1/fulltext
Title :
PCN95 Pharmacoeconomic Analysis of Direct Medical Costs Associated With the Treatment of Advanced Esophago-Gastric Cancer Therapy With Xeloda or 5-Fluorouracil (5-FU) Regimens- Implications for Health Care Utilisation in Australia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03849-1&doi=10.1016/j.jval.2012.08.2135
First page :
A426
Section Title :
Cancer
Open access? :
No
Section Order :
786